"Competition that can ramp up to 50 million test kits a day ?"
The conversation was not about the cheap antigen tests, it was examining the potential for the next generation QD tests that QMC is supposedly developing and when they may bring it to market.
Yes most understand that Innova is distributing large quantities of antigen and maybe antibody tests to a number of countries and that Innova is claiming that they can greatly increase the numbers by bring new production locations on line.
This certainly is good for Innova, Pasaca and Biotime since they have tremendous sales and growth potential.
But some investors are still looking for some confirmation that QMC is actually benefitting from all of these activities. Actual sales or royalties from the HID app, nanoparticles, QDs or blockchain usage.
What I did find interesting in the article that you linked to:
Mina and others said they have concerns about the equity of the Ellume test. It is priced at $30, far too expensive for most Americans to conduct frequent, regular screening at home. And the test is linked to a smartphone app that requires some tech savvy and steps that Mina and others said add difficulty and confusion for most potential users. The test kit transmits results to users via the app, and conveys data to local public health agencies to enable tracking case counts and contacts.
It appears that Mina is not necessarily a big fan of add-on technology to testing.